Latest stories on AUPH
AUPH Maintained by RBC Capital -- Price Target Raised to $18.00
GuruFocus63 · neutralanalyst
AUPH SWOT Analysis: Strong Revenue Growth and Market Position Highlighted in 10-Q Filing
GuruFocus58 · neutralgeneral
Aurinia Pharmaceuticals Raises Fy26 Revenue View 325m 330m From 315m 325m
The Fly64 · neutralearnings
Aurinia Pharmaceuticals reports Q3 EPS 23c, consensus 22c
The Fly56 · neutralearnings
Aurinia Pharma GAAP EPS of $0.23 beats by $0.01, revenue of $83.7M beats by $0.09M
Seeking Alpha58 · neutralearnings
Aurinia Pharmaceuticals Inc. (AUPH) files 8-K
SEC 8-K50 · neutralgeneral
Aurinia Pharmaceuticals price target raised to $18 from $17 at TD Cowen
The Fly63 · neutralanalyst
TD Cowen raises Aurinia Pharmaceuticals price target on cost outlook
Investing.com Analyst Ratings63 · neutralanalyst
Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside
Seeking Alpha53 · neutralproduct/pr
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company
Yahoo Top63 · neutralearnings
AUPH Trading Strategies for Aurinia Pharm Ord Stock
Barchart50 · neutralgeneral
Immatics and 4 More Stocks See Activist Action
Barron's55 · neutralgeneral
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
Yahoo Finance67 · bullishgeneral
Aurinia Shares Gains After Settling Patent Lawsuit With Teva
MarketWatch56 · neutralgeneral
Aurinia’s Patent Settlement with Teva Secures Voclosporin Exclusivity Until 2036
August 20, 2026
MarketChameleon67 · bullishgeneral
AUPH Stock Rallies 6% After-Hours — Here’s Why
Stocktwits News67 · bullishgeneral
Aurinia settles Lupkynis patent litigation with Teva
Seeking Alpha56 · neutralgeneral
Aurinia Settles Patent Infringement Lawsuit With Teva
MarketWatch56 · neutralgeneral
Aurinia stock falls on Teva patent settlement for voclosporin
Investing.com Markets34 · bearishgeneral
Aurinia Pharmaceuticals Inc. (AUPH) files 8-K
SEC 8-K50 · neutralgeneral
Aurinia Settles Patent Litigation with Teva
StockTitan56 · neutralgeneral
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Seeking Alpha56 · neutralproduct/pr
Aurinia Pharmaceuticals price target raised to $16 from $15 at RBC Capital
The Fly61 · neutralanalyst